MAASTRICHT UNIVERSITY Patent applications |
Patent application number | Title | Published |
20150038863 | NON-INVASIVE CLASSIFICATION OF ATRIAL FIBRILLATION BY PROBABILISTIC INTERVAL ANALYSIS OF A TRANSESOPHAGEAL ELECTROCARDIOGRAM - The invention relates to a computer-implemented method for determining an AF complexity value. The method includes applying a template matching algorithm to an ECG signal to obtain a set of candidate deflections and identifying intrinsic deflections within the set of candidate deflections. The method further includes determining a number of intrinsic deflections and a number of far-field deflections within the set of candidate deflections, based on the identified intrinsic deflections, and determining the AF complexity value as a ratio between the number of far-field deflections and the number of intrinsic deflections. | 02-05-2015 |
20130123314 | METHOD FOR IMPROVING CARTILAGE REPAIR AND/OR PREVENTING CARTILAGE DEGENERATION IN A JOINT - The invention is in the field of methods for medical treatment. It provides an improved method for repairing damaged cartilage and/or preventing cartilage degeneration in tissue, in particular in a joint by administering a pharmaceutically active agent directly into the fat pad of a joint. The pharmaceutically active agent is preferably selected from the group consisting of agents that stimulate chondrogenic differentiation and/or cartilage matrix synthesis; agents that inhibit osteogenesis and/or hypertrophy, anti-inflammatory agents, agents that inhibit apoptosis of chondrocytes, agents that inhibit senescence of chondrocytes and agents that enhance lubrication of a joint. | 05-16-2013 |
20100215731 | METHOD FOR IMPROVING CARTILAGE REPAIR AND/OR PREVENTING CARTILAGE DEGENERATION IN A JOINT - The invention is in the field of methods for medical treatment. It provides an improved method for repairing damaged cartilage and/or preventing cartilage degeneration in tissue, in particular in a joint by administering a pharmaceutically active agent directly into the fat pad of a joint. The pharmaceutically active agent is preferably selected from the group consisting of agents that stimulate chondrogenic differentiation and/or cartilage matrix synthesis; agents that inhibit osteogenesis and/or hypertrophy, anti-inflammatory agents, agents that inhibit apoptosis of chondrocytes, agents that inhibit senescence of chondrocytes and agents that enhance lubrication of a joint. | 08-26-2010 |